A detailed history of Massachusetts Financial Services CO transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Massachusetts Financial Services CO holds 1,540,840 shares of LYEL stock, worth $2.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,540,840
Previous 1,354,678 13.74%
Holding current value
$2.4 Million
Previous $2.63 Million 30.75%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$1.71 - $3.07 $318,337 - $571,517
186,162 Added 13.74%
1,540,840 $3.44 Million
Q4 2023

Feb 08, 2024

SELL
$1.39 - $2.35 $11,831 - $20,003
-8,512 Reduced 0.62%
1,354,678 $2.63 Million
Q3 2023

Nov 08, 2023

SELL
$1.45 - $3.35 $14,540 - $33,593
-10,028 Reduced 0.73%
1,363,190 $2 Million
Q2 2023

Aug 09, 2023

SELL
$1.89 - $3.86 $34,379 - $70,213
-18,190 Reduced 1.31%
1,373,218 $4.37 Million
Q1 2023

May 10, 2023

BUY
$1.97 - $3.58 $202,675 - $368,313
102,881 Added 7.98%
1,391,408 $3.28 Million
Q4 2022

Feb 13, 2023

BUY
$2.78 - $8.09 $635,591 - $1.85 Million
228,630 Added 21.57%
1,288,527 $4.47 Million
Q3 2022

Nov 09, 2022

BUY
$5.54 - $8.27 $397,705 - $593,686
71,788 Added 7.27%
1,059,897 $7.77 Million
Q2 2022

Aug 09, 2022

SELL
$3.68 - $6.8 $27,312 - $50,469
-7,422 Reduced 0.75%
988,109 $6.44 Million
Q1 2022

May 11, 2022

BUY
$5.05 - $7.7 $138,703 - $211,488
27,466 Added 2.84%
995,531 $5.03 Million
Q4 2021

Feb 10, 2022

SELL
$7.13 - $15.19 $50,801 - $108,228
-7,125 Reduced 0.73%
968,065 $7.49 Million
Q3 2021

Nov 10, 2021

SELL
$11.0 - $17.95 $140,118 - $228,647
-12,738 Reduced 1.29%
975,190 $14.4 Million
Q2 2021

Aug 13, 2021

BUY
$15.99 - $16.89 $15.8 Million - $16.7 Million
987,928 New
987,928 $16 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $387M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.